Myeloproliferative disorders: Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
Line 1: | Line 1: | ||
− | == |
+ | ==Criteria== |
+ | {| class="wikitable" |
||
− | {| |
||
− | ! |
+ | !Criterion |
+ | ![[Polycythemia vera|PV]] |
||
− | ! PV |
||
+ | ![[Essential thrombocythemia|ET]] |
||
− | ! ET |
||
+ | ![[Primary myelofibrosis|PMF]] |
||
− | ! PMF |
||
|- |
|- |
||
− | | |
+ | |CBC |
− | | |
+ | |Hb >165 (men) or >160 (women)<br />Hct >48% (men) or 49% (women)<br />RBC mass >25% predicted |
− | | |
+ | |Plts ≥450 |
− | | |
+ | |WBC ≥11 (minor)<br />Anemia (minor) |
|- |
|- |
||
− | | |
+ | |Bone marrow |
− | | |
+ | |Panmyelosis |
− | | |
+ | |Megakeryocytosis |
− | | |
+ | |Megakaryocytosis ± fibrosis |
|- |
|- |
||
− | | |
+ | |JAK2 |
− | | |
+ | |JAK2 or JAK2 exon 12 |
− | | |
+ | |JAK2, CALR, or MPL |
− | | |
+ | |JAK2, CALR, or MPL |
|- |
|- |
||
− | | |
+ | |Other |
− | | |
+ | |Low serum epo (minor) |
− | | |
+ | |Not otherwise explained<br />Clonal marker (minor)<br />Not reactive thrombocytosis |
− | | |
+ | |Not otherwise explained<br />Palpable spleen (minor)<br />High LDH (minor) |
|} |
|} |
||
Latest revision as of 08:17, 2 August 2020
Criteria
Criterion | PV | ET | PMF |
---|---|---|---|
CBC | Hb >165 (men) or >160 (women) Hct >48% (men) or 49% (women) RBC mass >25% predicted |
Plts ≥450 | WBC ≥11 (minor) Anemia (minor) |
Bone marrow | Panmyelosis | Megakeryocytosis | Megakaryocytosis ± fibrosis |
JAK2 | JAK2 or JAK2 exon 12 | JAK2, CALR, or MPL | JAK2, CALR, or MPL |
Other | Low serum epo (minor) | Not otherwise explained Clonal marker (minor) Not reactive thrombocytosis |
Not otherwise explained Palpable spleen (minor) High LDH (minor) |